Olympus 2006 Annual Report Download - page 11

Approach for Long-Term Growth
> With a forward-looking approach to long-term growth, Olympus
established the New Business Planning Division in April 2005.
This Division engages in new business development, pursuing
the creation of Olympus’ future core businesses.
In the medical and health field, for example, we are explor-
ing the possibility of entering the diagnostics business for the
early detection of carcinoma and the treatment thereof.
Maximize Corporate Value
> In the 2006 CSP, Olympus set the maximization of corporate
value as its management target, carried over from the previous
Corporate Strategic Plan, and vowed to make every effort to
optimize corporate worth through the recovery and enhance-
ment of value creation capabilities. In line with this, Olympus
aims for sales of ¥1,200 billion and operating profit of ¥100
billion in the final year of the Plan, namely fiscal 2009, ending
March 31, 2009.
We would appreciate the continued support and under-
standing of all of our shareholders.
June 2006
Tsuyoshi Kikukawa
President
technologies and the diagnostic testing business led by analyz-
ers and reagents. Expanding these businesses to the biotech-
nological field, Olympus can see further growth potential.
Olympus traces its origins to the micro-imaging (micro-
scopes) business, where, over the years, there has been an
incredible progression. Today, Olympus-developed technology
can observe living cells, the minimal unit of life, in three dimen-
sions. On the back of such epoch-making technology, we are
striving to participate in the drug discovery and molecular
pathology industries within the next three to five years.
In the diagnostic testing business, Olympus engages mainly
in the business of hemanalysis systems used in health exami-
nations and thorough medical checkups, but it plans to enter
the immunoassay field within one year and the genetics field
within three years. Though immunoassay is new territory for
Olympus, it can utilize the great know-how it has gained from
its expertise in the highly competitive hemanalysis industry.
Furthermore, by developing genetic analysis systems, Olympus
aims to participate in the personalized medicine business, pro-
viding treatment tailored to individual patients and thus to
become a key player in this newly developing industry.
Business Strategies in the Information &
Communication Business and Other Businesses
> In the Information & Communication Business and Other
Businesses, ITX Corporation leads the investment and con-
sultation activities of the IT- and medical-related businesses.
Olympus expects ITX Corporation to play a key role in the
development of new and creative businesses.
In the area of non-destructive testing, we will in the future
propose ideal solutions for maintenance systems, including
high-precision measuring technology and remote inspections.
In the industrial printers segment, we will supply products to sat-
isfy the needs of an expanding range of business scenarios.
Medical Systems Business Strategy Matrix
PR ODU CTS , SERV I CE S AND T ECH NO L OG IES
MAR KETS
Existing
Existing
Expanding/New
New
Growing
Endosurgery
and
Endotherapy
market
Increase
in VPP
programs
China
market
Capsule
endoscopes
LUCERA
successors
(EVIS LUCERA
SPECTRUM)
Develop new
procedures
and products
Imaging
Technologies
(Endosurgery)
Solutions
business
Special
lighting
technologies
Business
tie-ups
with Terumo
OLYM PUS 20 06 9